Altogen Labs, a preclinical Contract Research Organization (CRO) laboratory, has announced the successful validation of a comprehensive array of 10 lung cancer xenograft models. These models play a crucial role in testing the in vivo efficacy of novel therapeutics against lung cancer, potentially leading to significant advancements in the diagnosis, understanding, and treatment of primary lung carcinoma. In the field of lung cancer research, only around 20% of new drugs that show effectiveness in vitro also prove effective in vivo (Cancer Cell, 2017). By offering a variety of lung cancer xenograft models, the chances of success for new lung cancer therapies in humans can be significantly improved, leading to fewer failures in clinical trials and the development of more efficient and less toxic lung cancer drugs.

Altogen Labs provides multiple Patient-Derived Xenograft (PDX) models and has validated 10 in-house lung cancer xenograft models, including A549, H460, H226, NCI-H1975, DMS273, LL/2, Calu-3, Calu-6, H1155, and NCI-H522. These xenograft models involve the implantation of human lung cancer cells into immunocompromised SCID mice, either subcutaneously or orthotopically. These models are employed to predict the potential effectiveness and safety of therapies in human patients, ultimately reducing the exposure of patients to ineffective or harmful treatments.

Lung cancer ranks as the third most diagnosed cancer globally and is the leading cause of cancer-related deaths. In the United States, the five-year survival rate for lung cancer patients is just 17.4%, lower than many other forms of cancer. Preclinical research utilizing CDX (Cell Line Derived Xenograft) and PDX xenograft models plays a vital role in testing the efficacy and safety of new lung cancer treatments. These models allow researchers to study tumor behavior, test new cancer therapies, and investigate metastasis in vivo. The array of lung cancer xenograft models provided by Altogen Labs offers a comprehensive platform to capture the diverse characteristics of lung cancer, including its morphology, genetics, and stage-specific traits.